Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Abstract Text:

John R Hurst,Gerry Hagan,Jadwiga A Wedzicha,

BACKGROUND: Published data on antiinflammatory and immunomodulatory effects of statins suggest they may reduce mortality risks associated with an unchecked immune response to selected infections, including influenza and COPD. We assessed whether statin users had reduced mortality risks from these conditions. METHODS: We conducted a matched cohort study (n = 76,232) and two separate case-control studies (397 influenza and 207 COPD deaths) to evaluate whether statin therapy is associated with increased or decreased mortality risk and survival time using health-care encounter data for members of health maintenance organizations. For the cohort study, baseline illness risks from all causes prior to initiation of statin therapy were used to statistically adjust for the occurrence of outcomes after initiation of treatment. RESULTS: For moderate-dose (>/= 4 mg/d) statin users, this cohort study found statistically significant reduced odds ratios (ORs) of influenza/pneumonia death (OR, 0.60; 95% confidence interval [CI], 0.44 to 0.81) and COPD death (OR, 0.17; 95% CI, 0.07 to 0.42) and similarly reduced survival hazard ratios. Findings were confirmed with the case-control studies. Confounding factors not considered may explain some of the effects observed. CONCLUSIONS: This study found a dramatically reduced risk of COPD death and a significantly reduced risks of influenza death among moderate-dose statin users.

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Publishing Authors By Initials

JR Hurst,G Hagan,JA Wedzicha,

For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

PUBMED ID PMID:

MEDLINE DATE:

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Chest

VOLUME: 131

Page Numbers: 1006-12

Journal Abbreviation:

ISSN: 0012-3692

DAY: 27

MONTH: Apr

YEAR: 2007

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 231335

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Keywords Mesh Terms:

KEYWORDS: United States

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Information

Substance Name: Hydroxymethylglutaryl-CoA Reductase Inhi

Registry Number: 0

Grant and Affiliation Information for Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.

AFFILIATION: Health and Environmental Epidemiology Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA. ffrost@LRRI.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Chest

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins Related Publications

• A conceptual model for the study of the health action process.
• Carbamates in the chemotherapy of leukemia; observation of a possible antileukemic synergism between urethane and methyl-bis (beta-chloroethyl) amine.
• Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
• Combination therapy: some concepts and results.
• Decentralized medical education in rural communities: the circuit rider connection.
• Dietary intake and parents' perception of mealtime behaviors in preschool-age children with autism spectrum disorder and in typically developing children.
• Drug evaluation in experimental tumor systems: potential and limitations in 1961.
• Experimental adjuvant chemotherapy: an overview.
• Experimental clinical cancer chemotherapy. Philosophy at the preclinical level.
• Formation of giant solvation shells around fulleride anions in liquid ammonia.
• HYPOTHYROIDISM IN DIABETICS TREATED WITH SULPHONYLUREA.
• Homelessness and substance use among alcohol abusers following participation in project H&ART.
• Identification of Adducts Formed by Reaction of N-Acetoxy-3,5-dimethylaniline with DNA.
• Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.
• Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection.
• Observations of the retiring chairman of the Cancer Chemotherapy Review Board.
• Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.
• Physician behavior modification using claims data: tetracycline for upper respiratory infection.
• Proceedings: Successes and failures at the preclinical level; where now?
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.
• Steerable real-time sonographically guided needle biopsy.
• Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster.
• Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755.
• The "sensitivity" of resting and dividing cells.
• Treating the chemically dependent health professional.